For example, recent studies suggest that they could improve conditions ranging from depression to neurological disorders to cardiovascular and kidney disease
Children under 18 years old: Only as professionally prescribed
Potential candidates for off-label use: Clinicians may consider GLP-1 therapy for women with PCOS who meet the following criteria: Overweight or obesity (particularly BMI 30 kg/m) with PCOS Insulin resistance or impaired glucose tolerance Inadequate response to lifestyle modification and other treatments No contraindications to GLP-1 therapy Not planning pregnancy in the immediate future Contraindications and precautions: GLP-1 receptor agonists are contraindicated in pregnancy and breastfeeding
They go best with diet and exercise changes, and when used in moderation
Real-world data also suggest that most people discontinue GLP-1 therapy within the first year of treatment
A Semaglutide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Semaglutide, including repackagers and relabelers